✦ LIBER ✦

Results of treatment with high intensity, brief duration chemotherapy in poor prognosis non-hodgkin's lymphoma

✍ Scribed by Mary L. McMaster; John P. Greer; Steven N. Wolff; David H. Johnson; F. Anthony Greco; John D. Hainsworth; Richard S. Stein; John M. Flexner; John B. Cousar

Publisher: John Wiley and Sons
Year: 1991
Tongue: English
Weight: 848 KB
Volume: 68
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19910715)68:2<233::aid-cncr2820680203>3.0.co;2-q

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A brief-duration combination chemotherap

A brief-duration combination chemotherapy for elderly patients with poor-prognosis non-Hodgkin's lymphoma

✍ Mary L. McMaster; David H. Johnson; John P. Greer; Steven N. Wolff; Craig R. Hil 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 557 KB

High-dose cytosine arabinoside in previo

High-dose cytosine arabinoside in previously treated patients with poor-prognosis non-Hodgkin's lymphoma

✍ David J. Adelstein; Hillard M. Lazarus; John D. Hines; Roger H. Herzig 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 399 KB 👁 1 views

Non-melanoma skin cancer may be a marker

Non-melanoma skin cancer may be a marker of poor prognosis in patients with non-Hodgkin's lymphoma

✍ Henrik Hjalgrim; Morten Frisch; Hans H. Storm; Bengt Glimelius; Jakob Bøje Peder 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 French ⚖ 78 KB 👁 2 views

According to recent results, patients with non-melanoma skin cancers are at increased risk of developing non-Hodgkin's lymphoma (NHL). The prognostic significance of this association is unknown. Two cohorts of patients with a first diagnosis of non-melanoma skin cancer and a subsequent diagnosis of

Effect of chemotherapy on resting energy

Effect of chemotherapy on resting energy expenditure in patients with non-Hodgkin's lymphoma results of a sequential study

✍ Jacques Delarue; Eric Lerebours; Herve Tilly; Agnes Rimbert; Patrick Hochain; Cl 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 464 KB 👁 3 views

This study compared the resting energy expenditure (REE) modifications observed during successive intensive identical chemotherapy courses in non-Hodgkin's lymphoma patients to assess indirectly the metabolic changes induced by the cytotoxic effect of drugs on the tumor. With this therapeutic regime

Post-therapeutic acute malignant myelopr

Post-therapeutic acute malignant myeloproliferative syndrome and acute nonlymphocytic leukemia in non-Hodgkin's lymphoma correlation with intensity of treatment

✍ German A. Gomez; Kamlesh K. Aggarwal; Tin Han 📂 Article 📅 1982 🏛 John Wiley and Sons 🌐 English ⚖ 412 KB 👁 2 views

CEOP treatment results and validity of t

CEOP treatment results and validity of the International Prognostic Index in Chinese patients with aggressive non-Hodgkin's lymphoma

✍ C. S. Chim; Y. L. Kwong; A. K. W. Lie; C. K. Lee; R. Liang 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 125 KB 👁 2 views

From 1991 to 1997, we have treated 78 newly diagnosed patients with aggressive non-Hodgkin's lymphoma with a modified CHOP regimen in which epirubicin (60 mg/m 2 ) was used in place of doxorubicin (50 mg/m 2 ), i.e. CEOP (cyclophosphamide, epirubicin, vincristine and prednisolone). The median age wa